COMP <GO>
AUPH vs LLY // REVENUE GROWTH (YOY)
Aurinia Pharmaceuticals Inc (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: AUPH 5
— LLY 8
▲ REVENUE GROWTH (YOY) LEADER: LLY
LAST: $16.65 (-3.25%) • MKT CAP: $2.29B
revenue-growth
20.40%
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.29T
revenue-growth
45.51%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AUPH VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AUPH | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 88.50% | 83.64% | +4.86 | AUPH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 16.50% | 32.36% | -15.86 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.1x | 36.4x | -15.32 | AUPH | /valuation <GO> |
| Free Cash Flow Yield | 5.92% | 2.30% | +3.62 | AUPH | /fcf-yield <GO> |
| Operating Margin | 37.10% | 40.21% | -3.11 | LLY | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 31.90% | +36.10 | AUPH | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 20.40% | 45.51% | -25.11 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 8.33 | 9.29 | -0.96 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 9/9 | -2.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.3 | 66.6 | -9.30 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 6.7x | 30.6x | -23.92 | AUPH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.29B | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AUPH REV | LLY REV | AUPH GROSS % | LLY GROSS % | AUPH FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $283.1M | $65.18B | 88.5% | 83.0% | $135.7M | $16.81B |
| FY 2024 | $235.1M | $45.04B | 88.0% | 81.3% | $44.4M | $8.82B |
| FY 2023 | $175.5M | $34.12B | — | 79.3% | -$33.5M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AUPH // BETA —
LLY // BETA 0.51